Approaches to the Management of Non-Muscle Invasive Bladder Cancer: A Review of Current Guidelines and Best Practice Recommendations from the International Bladder Cancer Group

European Urology, Supplements

Volumn 7, Issue 10, 2008, Pages 615-617

  Brausi, Maurizio ^a  

^a AUSL Modena   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; TUMOR MARKER;

BLADDER CALCIFICATION; BLADDER CANCER; BLADDER CONTRACTION; BONE MARROW SUPPRESSION; CALCIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; CLINICAL PRACTICE; CONTACT DERMATITIS; CYSTITIS; DRUG HYPERSENSITIVITY; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEMATURIA; HUMAN; MEDICAL SOCIETY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; TREATMENT FAILURE; URETER OBSTRUCTION; UROGENITAL TRACT TUMOR;

EID: 51349142542     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.07.001     Document Type: Editorial

References (11)

1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J. European Association of Urology guidelines on TaT1 (non-muscle invasive) bladder cancer. Update March 2008. Arnhem, Netherlands: European Association of Urology; 2008. Available at: http://www.uroweb.org/fileadmin/tx_eauguidelines/TaT1 Bladder Cancer.pdf.
2. Soloway MS, ed. International consultation on bladder tumours. Urology 2005;66(Suppl 1):1-125.
3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer including upper tract tumours and urothelial carcinoma of the prostate. Version 1. Jenkintown, PA: NCCN; 2007.
4. American Urological Association. Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update. Linthicum, MD: AUA; 2007. Available at: http://www.auanet.org/guidelines/bladcan07.cfm.
5. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178 (2007) 2314-2330
6. Sylvester R.J., van der M., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
7. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
8. Böhle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 63 (2004) 682-686
9. Hinotsu S., Akaza H., Isaka S., et al. Sustained prophylactic effect of intravesical bacilli Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 67 (2006) 545-549
10. Sylvester R.J., Brausi M.A., Hoeltl W., et al. Long-term efficacy results of EORTC GU Group study 30911 comparing epirubicin, bacillus Calmette-Guérin (BCG), and BCG plus isoniazid in patients with intermediate and high-risk stage Ta T1 papillary carcinoma of the bladder. Eur Urol Suppl 7 (2008) 298
11. Van der Meijden A.P.M., Sylvester R.J., Oosterlinck W., Hoeltl W., Bono A.V., and for the EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 44 (2003) 429-434